Health Condition 1: M061- Adult-onset Stills disease Health Condition 2: M315- Giant cell arteritis with polymyalgia rheumatica Health Condition 3: M058- Other rheumatoid arthritis with rheumatoid factor Health Condition 4: M060- Rheumatoid arthritis without rheumatoid factor Health Condition 5: M45-M49- Spondylopathies Health Condition 6: M30-M36- Systemic connective tissue disorders
Conditions
Interventions
Intervention1: Methotrexate: The patients with AIRD randomized to two groups - one group continues methotrexate
Route oral and Sub cutaneous ,
Dose and duration - same dose as the patient is tak
Sponsors
Centre for Arthritis and Rheumatism Excellence CARE
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion Criteria Patient above 18 years of age. Patients willing to give consent for the study Patients with a prior diagnosis of Autoimmune Rheumatic disease(AIRD) stable dose for at least the past 2 months
Exclusion criteria
Exclusion criteria: Exclusion Criteria Patients who had covid-19 infection in the past. Patients with history of allergy to vaccine components . Prior GBS/demyelinating syndromes Any live vaccine taken within prior 4 weeks or inactivated vaccine in last 2 weeks before study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the anti spike/neutralizing antibody titre and T cell ELIspot assay will be assessed 1 month after the second dose of vaccine and to see if there is statistically significant difference among the two groups studiedTimepoint: 1 month post 2nd dose vaccine | — |
Secondary
| Measure | Time frame |
|---|---|
| NilTimepoint: NA | — |
Countries
India
Contacts
Public ContactDr S Anu
Dr Shenoy�s Care Private Limited
Outcome results
None listed